Selling, General, and Administrative Costs: Alkermes plc vs Novavax, Inc.

A Tale of Two Companies: SG&A Expenses Over Time

In the ever-evolving pharmaceutical landscape, understanding the financial strategies of key players is crucial. This chart provides a fascinating glimpse into the Selling, General, and Administrative (SG&A) expenses of Alkermes plc and Novavax, Inc. from 2014 to 2023. Over this period, Alkermes consistently outpaced Novavax in SG&A spending, with a notable increase of approximately 245% from 2014 to 2023. In contrast, Novavax's SG&A expenses surged dramatically by over 2,250% during the same period, reflecting its aggressive expansion and operational scaling. The year 2020 marked a pivotal point for Novavax, with expenses jumping nearly fourfold, likely due to its intensified efforts in vaccine development. This financial narrative underscores the strategic priorities of these companies, offering insights into their market positioning and growth trajectories.